Blueprint Medicines (BPMC) Projected to Post Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Blueprint Medicines to post earnings of ($0.44) per share and revenue of $158.31 million for the quarter.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, analysts expect Blueprint Medicines to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC traded up $1.57 during trading on Friday, reaching $87.66. 679,412 shares of the company's stock traded hands, compared to its average volume of 770,012. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines has a fifty-two week low of $73.04 and a fifty-two week high of $121.90. The company has a 50-day simple moving average of $87.57 and a 200-day simple moving average of $93.14. The firm has a market cap of $5.60 billion, a PE ratio of -81.17 and a beta of 0.75.

Insider Activity

In related news, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares of the company's stock, valued at $6,581,655.32. This trade represents a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares of the company's stock, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.21% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on BPMC. Wedbush reiterated an "outperform" rating and issued a $128.00 target price on shares of Blueprint Medicines in a research report on Wednesday, April 16th. StockNews.com lowered Blueprint Medicines from a "hold" rating to a "sell" rating in a research note on Monday, March 3rd. Stephens reissued an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research note on Thursday, January 2nd. JPMorgan Chase & Co. raised their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Finally, Wolfe Research began coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They set an "outperform" rating for the company. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines currently has an average rating of "Moderate Buy" and a consensus target price of $124.68.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.